Essential thrombocytosis laboratory findings: Difference between revisions
(Created page with "{{Essential thrombocytosis}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Hematology [[Category:Oncolog...") |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
==Diagnostic criteria== | |||
The diagnosis of essential thrombocytosis requires the presence of a persistent thrombocytosis of greater than 600 x10<sup>9</sup>/L in the absence of an alternative cause. | |||
The following revised diagnostic criteria for essential thrombocytosis were proposed in 2005 <ref name=Campbell>Campbell PJ, Green AR. ''Management of Polycythemia Vera and Essential Thrombocythemia.'' Hematology (Am Soc Hematol Educ Program). 2005;:201-8. PMID 16304381</ref>. The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6. | |||
* A1. Platelet count > 600 x 10<sup>9</sup>/L for at least 2 months | |||
* A2. Acquired V617F JAK2 mutation present | |||
* B1. No cause for a reactive thrombocytosis | |||
** normal inflammatory indices | |||
* B2. No evidence of iron deficiency | |||
** stainable iron in the bone marrow or normal red cell mean corpuscular volume | |||
* B3. No evidence of [[polycythemia vera]] | |||
** hematocrit < midpoint of normal range or normal red cell mass in presence of normal iron stores | |||
* B4. No evidence of chronic myeloid leukemia | |||
But the Philadelphia chromosome may be present in up to 10% of cases. Patients withe the Philadelphia chromosome have a potential for the development of acute leukemia, especially acute lymphocytic leukemia. | |||
* B5. No evidence of [[myelofibrosis]] | |||
** no collagen fibrosis and ≤ grade 2 reticulin fibrosis (using 0–4 scale) | |||
* B6. No evidence of a myelodysplastic syndrome | |||
** no significant dysplasia | |||
** no cytogenetic abnormalities suggestive of myelodysplasia | |||
==References== | ==References== | ||
Revision as of 22:02, 20 January 2012
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis laboratory findings |
|
Risk calculators and risk factors for Essential thrombocytosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diagnostic criteria
The diagnosis of essential thrombocytosis requires the presence of a persistent thrombocytosis of greater than 600 x109/L in the absence of an alternative cause.
The following revised diagnostic criteria for essential thrombocytosis were proposed in 2005 [1]. The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6.
- A1. Platelet count > 600 x 109/L for at least 2 months
- A2. Acquired V617F JAK2 mutation present
- B1. No cause for a reactive thrombocytosis
- normal inflammatory indices
- B2. No evidence of iron deficiency
- stainable iron in the bone marrow or normal red cell mean corpuscular volume
- B3. No evidence of polycythemia vera
- hematocrit < midpoint of normal range or normal red cell mass in presence of normal iron stores
- B4. No evidence of chronic myeloid leukemia
But the Philadelphia chromosome may be present in up to 10% of cases. Patients withe the Philadelphia chromosome have a potential for the development of acute leukemia, especially acute lymphocytic leukemia.
- B5. No evidence of myelofibrosis
- no collagen fibrosis and ≤ grade 2 reticulin fibrosis (using 0–4 scale)
- B6. No evidence of a myelodysplastic syndrome
- no significant dysplasia
- no cytogenetic abnormalities suggestive of myelodysplasia
References
- ↑ Campbell PJ, Green AR. Management of Polycythemia Vera and Essential Thrombocythemia. Hematology (Am Soc Hematol Educ Program). 2005;:201-8. PMID 16304381